Decreased plasma epidermal growth factor (EGF) levels in patients with severe chronic obstructive pulmonary disease
Pneumologia · 2019
DOI: 10.2478/pneum-2019-0004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pneumologia, 2019. Verfasst von Retno AS Soemarwoto und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 3.0).
Themen: COPD
Abstract (Originalsprache)
Background
Chronic mucus hypersecretion is a common feature in chronic obstructive pulmonary disease (COPD) and is associated with epidermal growth factor (EGF) activity. Aberrant EGF and its receptor signalling can cause airway hyperproliferation, increase in mucous cell differentiation and mucus hyperproduction. Furthermore, it can also promote subepithelial fibrosis and excessive collagen deposition in COPD. The objective of this research was to investigate the plasma levels of EGF in smokers with COPD in comparison with clinically healthy smokers. In addition, the relationship between the plasma levels of EGF and clinical features was investigated.
Methods
A cross-sectional study included 82 clinically stable male patients with mild-to-very severe COPD (mean age: 64.5±8.6 years), and the control group consisted of 86 healthy male smokers (mean age: 61.6±9.5 years). To define COPD, we performed spirometry and classified COPD using Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification. We analyzed the levels of EGF by enzyme-linked immunosorbent assay in plasma.
Results
The mean serum levels of EGF were significantly lower in smokers with COPD than those in controls (69.30 and 83.82 pg/mL, respectively, p = 0.046). The plasma levels of EGF were significantly different (p = 0.004) between mild COPD and moderate-to-very severe COPD. There were no significant differences between the levels of EGF in plasma of spontaneous sputum producers (COPD patients) vs. nonsputum producers (p = 0.101) and between nonexacerbated COPD and exacerbated COPD patients(p = 0.138).
Conclusions
There is a significant difference in the plasma levels of EGF in male smokers with COPD as compared with male healthy smokers. Our findings suggest that the plasma levels of EGF may contribute to the pathogenesis of COPD.
Zitieren
APA
Soemarwoto, R. A., Jamsari, Yanwirasti, Putra, A. C., & Mustofa, S. (2019). Decreased plasma epidermal growth factor (EGF) levels in patients with severe chronic obstructive pulmonary disease. Pneumologia. https://doi.org/10.2478/pneum-2019-0004
Vancouver
Soemarwoto RA, Jamsari, Yanwirasti, Putra AC, Mustofa S. Decreased plasma epidermal growth factor (EGF) levels in patients with severe chronic obstructive pulmonary disease. Pneumologia. 2019. doi:10.2478/pneum-2019-0004
BibTeX
@article{Soemarwoto2019,
author = {Soemarwoto, Retno AS and Jamsari and Yanwirasti and Putra, Andika Chandra and Mustofa, Syazili},
title = {Decreased plasma epidermal growth factor (EGF) levels in patients with severe chronic obstructive pulmonary disease},
journal = {Pneumologia},
year = {2019},
doi = {10.2478/pneum-2019-0004}
}
EUVIMED